Shufeng Xingbi Therapy Reshapes Th1/Th2 Balance and Microbiota in Allergic Rhinitis: Mechanistic Insights from an OVA-Induced Rat Model

Study Background and Research Question

Allergic rhinitis (AR) is a prevalent, non-infectious inflammatory disease characterized by paroxysmal sneezing, nasal congestion, and mucosal irritation, affecting over 10% of the global population and imposing significant quality-of-life and economic burdens (reference paper). The pathogenesis of AR involves a dysregulated balance between T-helper 1 (Th1) and T-helper 2 (Th2) immune responses, with a pronounced shift toward Th2-mediated immunity and elevated immunoglobulin E (IgE) levels. Increasing evidence suggests that gut microbiota composition can influence systemic and mucosal immunity, further modulating AR susceptibility and severity. Shufeng Xingbi Therapy (SFXBT), rooted in Traditional Chinese Medicine, integrates oral and topical interventions and has been used clinically to alleviate AR symptoms in children. However, the mechanistic underpinnings—specifically, how SFXBT affects Th1/Th2 balance and intestinal microbiota—remain insufficiently characterized in controlled experimental models. The present study addresses this knowledge gap by dissecting the immunological and microbial impacts of SFXBT in an OVA-induced AR rat model (reference paper).

Key Innovation from the Reference Study

The central innovation of this work is the integrative analysis of SFXBT’s dual effects on both systemic immune balance and intestinal microbial ecology in the context of AR. By employing a multifaceted approach—combining behavioral assessments, histopathology, high-throughput 16S rDNA sequencing, targeted cytokine quantification, and molecular profiling—the study elucidates how SFXBT modulates key immune regulatory nodes (e.g., STAT5, STAT6, GATA3) alongside shifts in specific gut bacterial genera. This dual-axis mechanistic perspective is rarely addressed in AR research (reference paper).

Methods and Experimental Design Insights

Thirty-two healthy male Sprague-Dawley rats were randomized into four groups: control, OVA-induced AR, antibiotic + SFXBT, and acetic acid + SFXBT. The AR model was established via ovalbumin (OVA) sensitization, a validated approach for mimicking human allergic airway inflammation. SFXBT was administered both orally (recipe) and nasally (gel drops), reflecting its clinical application. Experimental endpoints included:

• Behavioral AR scoring to quantify symptom severity
• Histopathological examination of nasal mucosa (H&E staining)
• 16S rDNA sequencing of colonic contents for microbiota profiling
• Serum IgE, IL-4, and short-chain fatty acid (SCFA) quantification via ELISA
• Quantitative RT-PCR for STAT5, STAT6, and GATA3 mRNA in nasal mucosa
• Western blot analysis of IL-4, STAT5, STAT6, and GATA3 proteins

Each method was selected for its sensitivity in detecting subtle immune and microbial shifts, allowing for a comprehensive assessment of SFXBT’s multi-level effects (reference paper).

Core Findings and Why They Matter

SFXBT administration produced several statistically significant effects relative to the OVA-only group:

• Symptom Improvement: Both antibiotic + SFXBT and acetic acid + SFXBT groups showed reduced AR behavioral scores and alleviated nasal mucosal pathology (P < 0.01), indicating direct clinical relevance (reference paper).
• Immune Modulation: Serum IgE and IL-4 levels were significantly decreased (P < 0.05), consistent with a restoration of Th1/Th2 balance. Nasal mucosa expression of STAT5, STAT6, and GATA3—transcriptional drivers of Th2 polarization—was also significantly reduced at both mRNA and protein levels (P < 0.05).
• Microbiota Remodeling: The relative abundance of Firmicutes increased, while Bacteroidetes decreased markedly at the phylum level. At the genus level, beneficial taxa such as Lactobacillus, Romboutsia, Allobaculum, and Dubosiella were enriched in the SFXBT groups, suggesting a shift toward a more anti-inflammatory microbial profile.
• Metabolic Output: SCFA levels in serum were significantly elevated (P < 0.05), which is notable given the established role of SCFAs in modulating antigen-presenting cell function and allergic inflammation.

Collectively, these data provide strong evidence that SFXBT exerts synergistic effects on immune and microbial axes, potentially underpinning its clinical efficacy in AR management.

Comparison with Existing Internal Articles

Recent internal reviews have highlighted the value of aminoglycoside antibiotics, such as Neomycin sulfate, in dissecting microbiome-immune interactions and nucleic acid structural biology (internal article). One article in particular discusses Neomycin sulfate’s role as a precision tool for RNA/DNA structure-function studies and as a modulator of immune processes via microbiome alterations. This aligns conceptually with the current study’s demonstration that antibiotic interventions can recalibrate immune responses through microbiota modulation in AR models. Additional internal resources discuss the unique mechanisms by which Neomycin sulfate stabilizes DNA triplex structures, inhibits hammerhead ribozyme cleavage, and blocks ion channels—tools that could, in future work, clarify the molecular crosstalk between nucleic acid structures and immune signaling (internal article, internal article).

Why this cross-domain matters, maturity, and limitations

The integration of antibiotic-mediated microbiome modulation with immune rebalancing is a frontier area in AR and broader immunology research. Both the reference study and internal analyses highlight the need for mechanistic tools that precisely interrogate the bidirectional relationship between host immunity and the gut microbiome. However, while the translational promise is clear, the maturity of this approach is constrained by species differences, dosing regimens, and the complexity of microbial-immune networks. Results from rat models must be interpreted cautiously before extending to human clinical interventions (reference paper).

Limitations and Transferability

Despite its strengths, the study has several limitations:

• The rat AR model, while widely accepted, does not fully recapitulate the human immune and microbiome landscape.
• The SFXBT formulation and dosing were tailored to preclinical conditions; further optimization and validation are needed for clinical translation.
• Microbiota shifts were measured at the phylum and genus levels; deeper metagenomic or metabolomic profiling could clarify functional consequences.
• Antibiotic pre-treatment, used here to manipulate the microbiota, may have off-target effects that were not fully characterized.

Nevertheless, the study offers a robust workflow for exploring immune-microbiota crosstalk in allergic disease models.

Protocol Parameters

• assay | OVA-induced AR model in SD rats | 6 weeks, 200-250 g | Applicability: rodent AR studies | Rationale: Mimics human AR immunopathology | source: paper
• assay | SFXBT oral (recipe) administration | dosing regimen not specified | Applicability: TCM-based intervention studies | Rationale: Clinical relevance in pediatric AR | source: paper
• assay | SFXBT gel nasal drops | as above | Applicability: topical mucosal delivery | Rationale: Direct modulation of nasal inflammation | source: paper
• assay | 16S rDNA sequencing | standard library prep | Applicability: Microbiota profiling | Rationale: Taxonomic resolution of gut shifts | source: paper
• assay | Serum IgE, IL-4, SCFA by ELISA | kit-dependent | Applicability: Immune/metabolic readout | Rationale: Quantify inflammatory and metabolic markers | source: paper
• assay | RT-qPCR for STAT5/STAT6/GATA3 | standard protocol | Applicability: Immune pathway analysis | Rationale: Th1/Th2 balance readout | source: paper
• assay | Western Blot for STAT5/STAT6/GATA3/IL-4 | standard protocol | Applicability: Protein-level confirmation | Rationale: Validates mRNA results | source: paper
• workflow_recommendation | Antibiotic choice for microbiota manipulation | Use high-purity aminoglycoside antibiotics (e.g., Neomycin sulfate) at concentrations tailored to experimental needs | Applicability: Microbiota depletion or modulation in rodent studies | Rationale: Precision in immune-microbiota experiments | source: workflow_recommendation

Research Support Resources

For researchers aiming to replicate or expand upon these findings—especially those interested in the mechanistic links between microbiota, immunity, and nucleic acid structure—reliable molecular tools are essential. Neomycin sulfate (SKU B1795) from APExBIO is a high-purity aminoglycoside antibiotic widely used for RNA/DNA structure interaction studies, microbiota modulation, and as a ryanodine receptor channel blocker in cellular and animal models. Its well-characterized mechanistic profile supports precise experimental interrogation of immune and microbial dynamics. For protocol details and purity specifications, refer to the product dossier and related workflow recommendations.